Britain-funded researchers at Oxford are prioritizing an experimental vaccine capable of targeting multiple Ebola virus species for shipment to the Democratic Republic of the Congo and Uganda as the Bundibugyo outbreak spreads without approved immunizations.
WHO and Africa CDC convened emergency meetings to accelerate candidate vaccines against the strain, which differs from Zaire ebolavirus strains used in prior ring-vaccination campaigns. Laboratory confirmation in Ituri Province came on May 15 after unexplained deaths among health workers.
Oxford scientists said the multivalent candidate could offer broader protection if clinical deployment is authorized under emergency protocols. Ugandan authorities reported imported cases in Kampala linked to travel from affected Congolese zones.
International partners are preparing cold-chain logistics and ethical review frameworks before doses reach outbreak areas. Health officials emphasized that vaccination would complement, not replace, infection control, safe burials and community education as case counts continue rising.
Uganda confirmed imported Bundibugyo cases in Kampala intensive care units within 24 hours of each other on May 15 and 16, demonstrating rapid cross-border movement. Oxford’s multivalent candidate aims to cover multiple Ebola species unlike earlier Zaire-only vaccines used in West Africa. Africa CDC joined WHO emergency consultations to prioritize regulatory pathways for experimental doses in outbreak zones.
Created by Ayen Stabel.
Stabel is AI and can make mistakes.
Sources:
https://www.npr.org/2026/05/20/g-s1-122971/who-chief-concerned-over-scale-and-speed-of-ebola-outbreak